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Abstract
Background: Ebola virus causes severe, often fatal hemorrhagic fever in humans. The mechanism
of escape from cellular anti-viral mechanisms is not yet fully understood. The promyelocytic
leukaemia (PML) associated nuclear body is part of the interferon inducible cellular defense system.
Several RNA viruses have been found to interfere with the anti-viral function of the PML body. The
possible interaction between Ebola virus and the PML bodies has not yet been explored.
Results: We found that two cell lines, Vero E6 and MCF7, support virus production at high and
low levels respectively. The expression of viral proteins was visualized and quantified using high
resolution immunofluorescence microscopy. Ebola encoded NP and VP35 accumulated in
cytoplasmic inclusion bodies whereas VP40 was mainly membrane associated but it was also
present diffusely in the cytoplasm as well as in the euchromatic areas of the nucleus. The anti-VP40
antibody also allowed the detection of extracellular virions. Interferon-alpha treatment decreased
the production of all three viral proteins and delayed the development of cytopathic effects in both
cell lines. Virus infection and interferon-alpha treatment induced high levels of PML protein
expression in MCF7 but much less in Vero E6 cells. No disruption of PML bodies, a common
phenomenon induced by a variety of different viruses, was observed.
Conclusion: We have established a simple fixation and immunofluorescence staining procedure
that allows specific co-detection and precise sub-cellular localization of the PML nuclear bodies and
the Ebola virus encoded proteins NP, VP35 and VP40 in formaldehyde treated cells. Interferon-
alpha treatment delays virus production in vitro. Intact PML bodies may play an anti-viral role in
Ebola infected cells.
Background
Ebola virus belongs to the family of negative strand RNA
viruses (Mononegavirales) and together with the Marburg
virus are the two known species of the Filoviridae family
[1]. Electron microscopy of Ebola virions produced in cell
culture have shown them to be pleomorphic, appearing as
either 6-shaped, circular or as long filamentous (and
sometimes branched) forms with a length up to 14,000
nm and a uniform diameter of 80 nm [2]. The 19 kb sin-
gle-stranded RNA genome encodes seven viral proteins:
the membrane associated (matrix) proteins VP24 and
VP40, the viral glycoproteins, GP (that forms the 10 nm
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long peplomers) and sGP (non-structural secreted form),
the characteristic helical ribonucleocapsid that consists of
the nucleoprotein (NP), VP30, VP35 and the L-protein
that forms a RNA-dependent RNA polymerase [1].
Infection of humans and non-human primates by the Eb-
ola virus often leads to severe disease, characterized by
systemic hemorrhage, with mortality rates from around
50% up to nearly 90% [3]. The underlying pathogenic
mechanism of the hemorrhagic fever is poorly under-
stood. A major reason for the limited amount of informa-
tion regarding these types of viruses is that the handling of
these agents requires a biological safety level 4 (BSL4)
containment laboratory.
The reason for the severe tissue damage and organ failure
is still somewhat obscure. Both direct cytolysis by the virus
and indirect pathology induced by immune-mediated re-
sponses have been suggested to play a role [4,5]. Several
studies have suggested that the viral GP (the presumed at-
tachment protein) is one of the major pathogenic factors
[6,7].
It is not yet clear how the virus evades cellular anti-viral re-
sponses. Certain studies have indicated that a strong in-
flammatory response early in infection may be beneficial
for the survival of the infected individual [8]. In a murine
model system it was shown that the type I interferon
(IFN) response plays a key role in the resistance of normal
mice to sub-cutaneously inoculated mouse-adapted Ebola
Zaire (EBO-Z) virus [9]. Successful filovirus therapy has
been suggested to require active participation of the type I
IFN response [9]. Emerging data suggests VP35 to func-
tion as a type I IFN antagonist [10].
Specific viral proteins are likely to contribute to the differ-
ent aspects of the pathology. An important aspect for un-
derstanding the function of the different viral proteins is
to characterize their precise sub-cellular localization and
behaviour during the different phases of viral life cycle.
High resolution localization of filovirus antigens is ham-
pered by the difficulties associated with handling of BSL4
agents. Complex, computer supported imaging systems
are not regular accessories of high containment level lab-
oratories. To use microscope systems placed at a BSL2 lab-
oratory requires complete inactivation of the virus e.g.
prolonged fixation of the infected cells with formalde-
hyde. This fixation procedure however renders most Ebola
antigens inaccessible for antibodies. Immunofluorescence
staining of formaldehyde fixed cells requires epitope re-
covery by means of limited proteolysis [11] or permeabi-
lization. Here we describe a simple fixation and
immunofluorescence staining protocol that allows specif-
ic and sensitive detection of three viral proteins (NP, VP35
and VP40) using the corresponding monoclonal antibod-
ies on infected cells that were fixed with formaldehyde for,
or in excess of, 48 hours. A subsequent treatment with an
acetone:methanol mixture served as permeabilization
step. We also carried out double immunofluorescence
staining of NP, VP35 and VP40 with promyelocytic leu-
kaemia (PML) associated protein, a major component of
the subnuclear organelle nuclear domain 10 (ND10; PML
body).
The nuclear PML body was first identified as involved in
the pathogenesis of acute promyelocytic leukaemia [12].
These distinct sub-nuclear structures are present in most
mammalian nucleated cells and are part of an inducible
intracellular defense mechanism [13]. The constitutive
PML body expression is enhanced by type I and II IFN (al-
pha/beta and gamma) and in addition, the expression can
be induced by viral infections, thereby displaying a de-
fense mechanism to viruses [13]. Many viral infections re-
sults in the PML body disruption or delocalization.
Various viral proteins from viruses such as lymphocytic
choriomeningitis virus (LCMV) [14,15], human T-cell
leukaemia virus type 1 (HTLV-I) [16], Rabies virus [17],
Epstein-Barr virus (EBV) [18,19] and herpes simplex virus
(HSV) [20] have been found to associate with PML bodies
and interfere with its innate anti-viral function. Some viral
proteins have been found to either physically associate
with the PML body [13] or indirectly relocate its normal
intra-nuclear positioning, thereby disrupting the normal
PML body function. However, precise mechanisms for
"disruption and delocalization" are not well understood.
To date, no data are published on the potential interaction
between filovirus proteins and the PML nuclear bodies.
In this study, we report our observations concerning the
sub-cellular localization of these proteins in two different
cell lines (Vero E6 and MCF7) that show different sensitiv-
ity for Ebola infection. We have measured the levels of the
viral proteins at different time points post-infection in
IFN-alpha treated and non-treated cells using digital im-
age quantification methods. We also correlated the ex-
pression of viral proteins with the expression of PML
protein.
Results
Immunofluorescence detection of Ebola antigens
Staining of viral antigens outside a BSL4 laboratory re-
quires complete inactivation of the virus. This was
achieved by fixation of the infected cells with 4% buffered
formaldehyde for 48 hours. To permeabilize the cells and
recover the epitopes we treated the fixed cells with a 1:1
mixture of methanol and acetone for additional 12–24
hrs. Two different cell types, the human cell line MCF7
and the monkey-derived Vero E6 were used in this study.
Both cell lines could be infected by the Ebola Zaire strainBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 1
Ebola virus infectivity differs in MCF7 and Vero E6 cells. Vero E6 (left panel) and MCF7 (right panel) cells at 24, 48 and 
72 hrs post-infection stained for Ebola virus nucleoprotein – NP (red). Cell nuclei are stained with Hoechst 33258 (blue).BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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(subtype Mayinga). Vero E6 cells were highly susceptible,
as seen by viral antigen expression by immunofluores-
cence. Nearly all cells were positive already 24 hrs post-in-
fection. In contrast, MCF7 cultures showed very few
infected cells at 24 hrs post-infection. Even after 72 hours
only around half of the cells contained viral antigens (Fig-
ure 1).
Sub-cellular localization of Ebola virus proteins
Nucleoprotein (NP)
All three antibodies directed against NP, VP35 and VP40
respectively gave a clear and distinct staining that was
completely absent from the non-infected cells. The strong-
est and most easily recognizable pattern, which was also
most clearly differing from existing cellular structures, was
obtained with the anti-NP antibody. It detected well cir-
cumscribed cytoplasmic inclusions of variable size. The
inclusions started as small round foci at the early phase of
infection. They then grew bigger, started to form tubular
structures with multiple branches and subsequently be-
came confluent, often surrounding the nucleus in a ring-
like fashion. High resolution, three dimensional reconsti-
tution of immunostained cells, from a series of mathe-
matically deblurred optical sections, showed that the
inclusions were not anchored to the cell membrane or to
the nucleus (Figure 2 top panel). At a late phase of infec-
tion the inclusions often turned into one or two nucleus
size bodies (Figure 3 middle panel). Importantly, the
presence of inclusions of often considerable size caused
no visible distress to the cells in the first 24–48 hours.
Cells with inclusions that occupied 1/3 to half of the cyto-
plasm had entered and successfully completed mitotic di-
visions (Figure 2 middle and bottom panels). Cytopathic
effects were only prominent in the Vero E6 cultures. At 72
hours many of the Vero E6 cells rounded up and subse-
quently died containing huge cytoplasmic inclusions.
Viral protein 35 (VP35)
VP35 was primarily associated with distinct NP-like cyto-
plasmic inclusions. Unlike NP, however, VP35 was also
distributed diffusely over the entire cytoplasm (Figure 3
bottom panel). No nuclear staining was detectable.
Viral protein 40 (VP40)
At an early stage of the infection VP40 showed fine granu-
lar, even distribution all over the cytoplasm. It was also
present in the nucleus avoiding the nucleoli (Figure 4 top
panel). At later stages of the infection VP40 became grad-
ually associated with the cell membrane. It was also still
present in the nuclei, mainly accumulating in the low
DNA density regions corresponding to the euchromatic
areas of the nucleus (Figure 3 top panel). In cells that start-
ed to round up VP40 was almost exclusively localized to
the cell surface. VP40 has been shown to be a membrane-
associated protein that induces formation of filamentous
virus-like particles [2,21]. Consistent with these findings,
we observed that VP40 was present in all the membrane
structures and, importantly, also in numerous filamen-
tous structures on the surface and in the vicinity of the in-
fected cell. The filamentous particles had a uniform
thickness, at the limit of the microscope resolution (<0.2
µm), but showed a great variability in length (0.4–10 µm)
as shown in Figure 4 middle and bottom panel. The size
and distribution of the particles and the known presence
of VP40 in the virion membrane implies that the anti-
VP40 antibody can detect Ebola virus particles and/or fil-
amentous virus-like particles outside the cell. Superposi-
tion of VP40 staining on the phasecontrast images of the
cells showed that virion release started before the appear-
ance of detectable cytopathic effects (Figure 5).
Interferon alpha (IFN-alpha) treatment delays Ebola infec-
tion in vitro
In order to examine the possible anti-viral effects, cell cul-
tures were pre-treated with IFN-alpha three hours before
the time of the infection. The IFN-alpha concentration
(200; 1,000 and 5,000 international units (IU)/ml) had
been previously tested on the cell lines and 200 IU/ml was
established to be the minimum concentration required
for up regulation of PML expression (data not shown).
This level also approximately corresponds to the in vivo
concentrations achieved during anti-viral therapeutic
treatment in patients. We observed that IFN-alpha treat-
ment markedly decreased the Ebola virus protein produc-
tion in both cell types. A pronounced effect was seen in
Vero E6 cultures with a 2 to 4-fold reduction in the
amount of viral proteins at 72 hrs post-infection (Figure
6). The expression levels were determined by quantifying
the fluorescence signals of approximately 1,200 cells in
three independent measurements on randomly selected
fields. The total signal intensity was divided by the
number of cells. The apparently paradoxal reduction of
NP expression per cell in MCF7 cultures at 72 hrs as com-
pared to 48 hrs (Figure 6 columns in the upper right
graph) was a result of the proliferation of non-infected
cells during the 3 days observation period. Plotting the
total amount of NP in the culture showed an almost linear
increase of NP expression in the non-treated cultures in
contrast to IFN-alpha treated cells (Figure 6 lines in the
upper right graph).
IFN-alpha treatment also delayed the appearance of cyto-
pathic effects. In non-treated Vero E6 cultures the majority
of infected cells eventually rounded up and detached from
the substratum. IFN-alpha treatment not only reduced the
size of NP inclusions but also inhibited the Ebola virus in-
duced round up (Figure 7).BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 2
Ebola virus NP in Vero E6 cells at different phases of the cell cycle. Stereoprojected images of NP (green) that show 
the three dimensional distribution of the protein in cytoplasmic inclusions in interphase, metaphase and anaphase. The images 
were reconstituted from a series of fifteen, mathematically deblurred, optical sections 0.3 µm apart. Note that the presence of 
large inclusions does not interfere with the progression of the cell cycle. Interphase nuclei and chromosomes are stained blue. 
Pictures were taken 48 hrs post-infection.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 3
Comparison of the sub-cellular distribution of Ebola viral proteins VP40, NP and VP35. Three dimensional stereo-
projected images of Vero E6 cells, 48 hours post-infection. DNA staining is blue. The upper panel shows that VP40 (green) is 
primarily membrane associated although it can be also present in the low DNA density regions of the nucleus or in diffuse 
areas of the cytoplasm. NP (green) on the other hand exclusively accumulates in well circumscribed cytoplasmic inclusions of 
various size, shape and confluency (middle panel). VP35 (green) shows similar distribution as NP with additional homogeneous 
staining all over the cytoplasm (bottom panel). Both NP and VP35 avoid the nuclei.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 4
Ebola VP40 changes distribution during the course of infection. The stereoprojected images of MCF7 cells show that 
at the early phase of infection (top panel) VP40 is localized to homogeneously dispersed granules in the cytoplasm as well as in 
the nucleus. Later, at the initial phase of rounding up (middle panel), VP40 is almost exclusively membrane associated and it is 
present in extracellular filamentous structures as well. VP40 is also present in the virions that accumulate in large quantities 
around cells with pronounced cytopathic effects (bottom panel). DNA staining is blue.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 5
Release of filamentous Ebola virus particles from Vero E6 cells. VP40 staining (red) superimposed on a phasecontrast 
image of infected cells shows the appearance of extracellular virions even before the development of cytopathic effects. DNA 
staining is blue.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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PML expression in Ebola infected cultures
Ebola infection led to an increased expression of PML pro-
tein in MCF7 cultures whereas PML levels were not
changed in mock-infected cells at any time point (data not
shown). IFN-alpha treatment further increased PML pro-
tein expression. The elevation of PML levels was manifest-
ed in the increased size and staining intensity of the PML
nuclear bodies. The increased PML expression corre-
sponded to an overall decrease of Ebola virus protein ex-
pression. On the other hand Vero E6 cultures showed an
overall low level of PML expression with small and less in-
tensely stained nuclear bodies. Virus infection and IFN-al-
pha treatment was much less efficient in increasing PML
expression in this cell type (Figure 8).
Double immunofluorescence staining of the three Ebola
proteins (VP35, VP40 and NP in MCF7 and Vero E6 cells)
in combination with PML showed that increased PML ex-
pression was associated mainly with the infected cells (as
visualized in Figure 9 by VP35 and VP40 expression in
MCF7 and NP expression in Vero E6). No disruption or
dissolution of PML bodies was observed in the infected
cells of either cultures.
Discussion
We could demonstrate that 4% formaldehyde fixation fol-
lowed by acetone: methanol (1:1) treatment allowed the
immunofluorescence detection of both the Ebola virus
proteins NP, VP35, VP40 and the cellular PML protein in
the virus infected cells. In fact, the fixation procedure was
fully comparable with fixation in acetone alone (data not
shown). This method provides an easier, and in routine
laboratory procedure more reliable, alternative to the pro-
tocols of van der Groen [22] and Kurata [11] where the
epitope recovery in formaldehyde fixed cells required con-
trolled enzymatic treatment with trypsin or pronase. It
gives a comparable result to paraformaldehyde fixation
followed by Triton X-100 permeabilization [6].
Our staining data suggest that for routine detection of in-
fectious virus or titration of virus stocks, immunofluores-
cence staining of NP protein (since staining of this protein
gave rise to the most easily recognizable pattern, clearly
differing from existing cellular structures) on formalde-
hyde fixed and subsequently methanol:acetone treated
cells, is a useful tool.
The presence of NP-containing viral inclusions through-
out the cell cycle indirectly suggests that Ebola virus does
not induce an immediate re-programming of the cells by
abruptly shutting down host protein synthesis but pre-
pares for virus replication in a much more stealth-like
fashion. The development of huge cytoplasmic inclusions
without apparent cellular distress is in line with previous
Figure 6
Interferon-alpha treatment inhibits the production of 
Ebola virus proteins. 200 IU/ml of IFN-alpha reduces the 
amount of NP, VP35 and VP40 both in the highly susceptible 
Vero E6 cells and in the less virus sensitive MCF7 cells. The Y 
axis shows the relative fluorescence intensity. The columns 
represent the mean fluorescence intensity per cell. Standard 
deviation was calculated from three independently captured 
random fields of immunostained cells. All the steps of IFN-
alpha treatment, virus infection, fixation, immunofluores-
cence staining and image capturing were carried out in paral-
lel for the two cell lines allowing the direct comparison of 
expression levels of the individual viral proteins between 
treated and non-treated as well as between Vero E6 and 
MCF7 cell lines. This is represented by the identical scale of 
the Y axis for the given proteins. Due to the unknown bind-
ing affinity of the antibodies the staining intensities for NP, 
VP35 and VP40 are not comparable with each other. To 
avoid confusion due to the presence of an expanding non-
infected cell population in the MCF7 cultures we show not 
only the fluorescence intensity of staining per cell (columns of 
the upper right chart) but also the average fluorescence 
intensity for the entire field (lines – with a corresponding Y 
axis on the right).BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Figure 7
Interferon-alpha treatment decreases the Ebola virus induced cytopathic effects in Vero E6 cultures. Phasecon-
trast image of IFN-alpha treated and non-treated cells 72 hrs post-infection shows an efficient inhibition of rounding up (top 
right panel). Fluorescence staining for NP (red) and DNA (blue) is superimposed on the phase contrast image (bottom panel).BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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observations that filoviruses induced cytopathic effects
may be absent or require several days to manifest [23].
VP35 is an essential component of the Ebola nucleocapsid
[24]. Here we show that VP35 accumulates in cytoplasmic
inclusions that are morphologically indistinguishable
from NP-containing viral inclusions. Ebola virus repli-
cates in the cytoplasm through double stranded RNA in-
termediates and it appears that it has evolved a
mechanism that interferes with dsRNA induced interferon
response [25]. VP35 was shown to be able to rescue NS1
mutant influenza A virus replication arguing that it is a
type I IFN antagonist. VP35 could also block dsRNA or vi-
rus-mediated induction of IFN responsive promoters [10].
Negative stranded RNA viruses often sequester their dsR-
NA intermediate into ribonucleoprotein complexes that
form cytoplasmic inclusions. The presence of VP35 in the
Ebola virus inclusions suggests that it intercepts the dsR-
NA induced response in a close spatial proximity to the vi-
ral RNA.
VP40 showed a completely different sub-cellular localiza-
tion from NP and VP35. It was primarily associated with
the cell membrane. Biochemical studies earlier showed
that VP40 is a membrane binding protein that oligomer-
izes upon interaction with lipid membranes [26]. The ol-
Figure 8
MCF7 and Vero E6 differs in the virus- and interferon treatment-induced PML expression levels. The Y axis 
shows the relative fluorescence intensity. The columns represent the mean fluorescence intensity of PML staining per nucleus in 
interferon-alpha treated cultures. Standard deviation is calculated from three independent capturings of random fields of immu-
nostained cells.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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igomerization leads to self assembly into membrane-
containing particles [27] and subsequent release into the
cell culture medium [28]. Unlike the Marburg virus en-
coded VP40 that localized both to the viral inclusions as
well as to clusters of intracellular membrane or to plasma
membrane protrusions in infected macrophages [29],
Ebola VP40 was primarily associated with the cell mem-
brane. It also entered the nucleus, similarly to the
Marburg encoded VP40, raising the possibility that VP40
may play additional, e.g. gene expression regulatory role
beside the involvement in virus assembly and budding.
Importantly, the staining with anti-VP40 antibodies on
formaldehyde fixed and acetone:methanol treated cells al-
lowed the direct immunofluorescence detection of extra-
cellular virions and/or filamentous virus-like particles.
The size of most viruses is regularly below the resolution
of the light microscope. Although the spatial resolution of
the fluorescence microscope is constrained by the same
physical laws as any other light microscopes, e.g. it does
not allow the reliable separation of two points that are
closer than 0.2 µm, it still allows the detection of light
emitting particles on dark background that are far much
Figure 9
Ebola virus induces increased PML expression in the infected cells. Double immunofluorescence staining of VP40 and 
VP35 in MCF7 or NP in Vero E6 cells (red) with PML (green) 48 hrs post-infection. The pictures shows that infected cells 
express more PML proteins as compared to the non-infected neighbouring cells. DNA staining is blue. The intensity of the PML 
fluorescence signal is not directly comparable between Vero E6 (weak overall PML staining) and MCF7 cells (strong overall 
PML staining).BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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smaller, e.g. individual protein molecules. Ebola Zaire vir-
ions with average length of 1.3 ± 0.7 µm and occasional
length up to 14 µm [2] are well within the limits of fluo-
rescence microscopy. The possibility to carry out 3D re-
constitution of fluorescence images picturing nascent
virions in combination with staining for additional two or
three viral and/or cellular proteins should provide ample
amount of information about the molecular mechanism
of the egress of Ebola virus.
IFN-alpha appears to play a crucial role in the anti-viral
defense in Ebola virus infected experimental animals.
Mice lacking the type I IFN receptor, but not wild type
mice, died upon subcutaneous inoculation of the virus
[9]. The adenosine analogue 3-Deazaneplanocin A was re-
cently shown to protect from Ebola virus induced death of
infected mice through massive induction of IFN-alpha
[30].
We found that IFN-alpha treatment decreased Ebola virus
protein production in vitro and inhibited the development
of cytopathic effects. These data are in line with the find-
ings that IFN-alpha could reduce infection 10 to 100-fold
in cell cultures and also delay the death of infected
monkeys [31]. One important anti-viral mechanism that
is induced as part of the interferon response is the in-
creased expression of the components of the subnuclear
organelle ND10 or PML body. A variety of DNA and RNA
viruses encode proteins that specifically interact with the
PML bodies and regularly destroy them. Rhabdoviruses
share several molecular features with filoviruses. The ra-
bies virus encoded P phosphoprotein is a distant homo-
logue of the Ebola VP35. It interacts with and reorganizes
PML bodies [17]. Here we show that Ebola virus infection
did not dissolve PML bodies. On the contrary, individual
cells expressing viral proteins regularly showed increased
expression of PML. Moreover, although Ebola virus
interferes with the IFN response it could not inhibit the
IFN-alpha mediated induction of PML. VP35, a possible
candidate for interference with PML function, never en-
tered the nucleus but remained exclusively cytoplasmic.
Importantly, Vero E6 cells, that supported Ebola replica-
tion very efficiently, expressed low levels of PML and
showed much smaller virus-dependent and IFN-mediated
increase in PML expression than MCF7 cells that served as
a poor host for the virus. Our data suggest that Ebola virus
lacks effective anti-PML mechanism. The data are also
consistent with the possibility that increased PML expres-
sion might hinder virus infection, similarly to what was
previously demonstrated for vesicular stomatitis virus
(VSV) [32,33], influenza virus [32], human foamy virus
(HFV) [34] and lymphocytic choriomeningitis virus (LC-
MV) [33]. Our results lead to the testable hypothesis that
introduction of constitutively expressed PML cDNA into
Vero E6 cells should inhibit, and inhibitory RNA (RNAi)
mediated downregulation of PML in MCF7 cells should
promote, the propagation of the Ebola virus in vitro.
Conclusions
A modified fixation procedure allowed us to study the ex-
pression levels and sub-cellular localization of Ebola virus
encoded proteins as well as the nuclear PML expression
using advanced imaging techniques. NP and VP35 accu-
mulated in cytoplasmic inclusion bodies whereas VP40
was mainly membrane associated. The anti-VP40 anti-
body stained extracellular virions and/or filamentous vi-
rus-like particles as well. We showed that the two cell lines
studied supported virus propagation on different levels:
Vero E6 – high, and MCF7 – low. IFN-alpha treatment de-
layed virus production in vitro in both lines. MCF7 but not
Vero E6 showed efficient virus- and IFN-mediated induc-
tion of PML. We suggest that Ebola virus lacks an effective
anti-PML mechanism and that intact PML bodies may
play an anti-viral role in Ebola virus infected cells.
Methods
Cell lines and interferon-alpha treatment
The human epithelial breast carcinoma cell line MCF7
(ATCC no. HTB-22) and the African green monkey kidney
cell line Vero E6 (originally named Vero C1008; ATCC no.
CRL-1586) were grown on 8-well Lab-Tek II Chamber
slides (Nunc, USA) in DMEM medium (high glucose)
supplemented with 10% fetal calf serum (Life
Technologies), penicillin/streptomycin, L-glutamine (Life
Technologies) at 37°C and 5% CO2. Cell cultures were
grown to sub-confluence and thereafter used as target cells
for the infections. Three hours pre-infection, selected cell
cultures were treated with 200 IU/ml of interferon-alpha
(Welferon; a generous gift from Dr. Norman Finter,
GlaxoWelcome).
Infections
All work with infectious material was carried out at the
BSL4 laboratory at the Center for Microbiological Prepar-
edness at the Swedish Institute for Infectious Disease Con-
trol in Solna, Sweden. Infections were performed with
Ebola Zaire subtype Mayinga (kindly provided by Dr
Stephan Becker, Marburg, Germany). The virus stock was
titrated on Vero E6 cells. For the experiments, the target
cells were infected with 2.3 plaque-forming units (PFU)
per cell (30,000 cells / well) in the total volume of 0.2 ml
for 45 min at 37°C. The supernatant was then removed
and 1 ml of fresh medium (D-MEM + 2% FCS) was added.
Cultures were incubated further and harvested at 1, 2 and
3 days post-infection. At harvest, chambers were removed,
slides were washed twice in PBS and subjected to fixation
(and virus inactivation) in 4% formaldehyde (10% NBF)
for 48 hr at +4°C.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/6
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Immunofluorescence staining
Infected cell cultures grown on 8-well Lab-Tek II Chamber
slides (Nalge Nunc International, IL, USA) were analysed
by indirect immunofluorescence 24 hrs, 48 hrs and 72 hrs
post-infection. After formaldehyde fixation slides were
quickly washed twice in PBS and permeabilized with ice-
cold aceton:methanol (1:1) 12–24 hrs at -20°C. Slides
were thereafter subjected to re-hydration in 2% FCS in
PBS for at least 1.5 hrs at room temperature (RT) before
incubated with primary anti-PML by using a rabbit-anti-
PML polyclonal (sc-5621, Santa Cruz Biotechnology). Pri-
mary antibodies were diluted in blocking buffer (2% BSA
/ 0.2% Tween-20 / 10% glycerol / 0.05% NaN3 in PBS)
and incubated in a moist chamber for 60 min at RT. Cells
were then washed five times with cold PBS before incuba-
tion with the secondary FITC-conjugated swine-anti-rab-
bit antibody (Dakopatts). The cells were then blocked
(absorbed) for 30 min in normal mouse serum in PBS.
Thereafter, Ebola viral proteins were stained by using the
following monoclonal antibodies (mouse ascitic fluids
from hybridoma cells generously provided by Dr Anthony
Sanchez at the Centers for Disease Control, Atlanta, GA
[2]): anti-EBOLA Zaire VP35 (BC03-BD09; EBO-Z-VP35);
EBOLA Zaire Nucleoprotein (FB03-BE08; EBO-Z-NP) and
EBOLA Zaire VP40 (BO04-BD07; EBO-Z-VP40). Ebola
monoclonals were diluted 1:100 in blocking buffer (2%
BSA / 0.2% Tween-20 / 10% glycerol / 0.05% NaN3 in
PBS) and incubated in a moist chamber for 60 min at RT.
Cells were thereafter washed five times in cold PBS and a
TRITC-conjugated rabbit-anti-mouse monoclonal anti-
body (Dakopatts) was added. Single staining of viral pro-
teins was carried out using the FITC-conjugated secondary
antibody. For DNA staining, Hoecht 33258 was used.
Cover slips were mounted on the glass slides using 70%
glycerol containing 2.5% DABCO anti-fading agent
(Sigma).
Fluorescence microscopy and digital image analysis
Images were collected using a Leitz DM RB microscope,
equipped with Leica PL Fluotar 100×, 40× and PL APO Ph
63× oil immersion objectives. Composite filter cubes were
used for the FITC, TRITC and Hoechst 33258 fluores-
cence, respectively. The pictures were captured with a
Hamamatsu dual mode cooled CCD camera (C4880),
recorded and analyzed on a Pentium PC computer
equipped with an AFG VISIONplus – AT frame grabber
board using Hipic4.0.4 (Hamamatsu), Image-Pro Plus
(Media Cybernetics). Digital images were assembled us-
ing Adobe Photoshop software.
Measurement of protein expression levels was carried out
on three randomly selected fields containing around 400
cells each. The slides were processed identically keeping
the exposition time, and the upper and lower limits of
computer LUT (look-up-table) constant. Fluorescence
intensities were calculated for individual cells. Average
and standard deviation values were calculated from the
three independent measurements.
3D reconstituted images were collected using Zeiss Axio-
phot microscope equipped with ×63 oil Plan-Apochromat
NA 1.4, and ×100 oil Plan-Neofluar NA 0.7–1.3 objec-
tives, illuminated with Osram HBO 200 W mercury short
arc lamp. A program, developed by us (RFH_ST_BIN), was
used to produce images. This program also gives informa-
tion about the depth distribution by creating a maximal-
intensity projected image pair representing a 3D reconsti-
tution of the original object as single or stereoscopic im-
age. To remove out-of-focus blur, the program uses the
nearest-neighbor deconvolution deblurring (NNDC) al-
gorithm. Following excitation filters were used: single
band UV exciter for Hoechst (84360), single band Blue ex-
citer for FITC (84490), and single band green exciter for
TRITC (84555). The images were captured with a PXL
cooled camera (Photometrics, Munich, Germany) and an-
alyzed using the Isee 5.1 graphical programming system
(Inovision, Raleigh; NC) on Pentium PC computer with
LINUX OS.
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